7,587.88

+46.48

+0.62%

51,874.09

-109.89

-0.21%

25,439.21

+274.84

+1.09%

2,829.39

+23.51

+0.84%

4.9540

+0.0600

+1.23%

20.41

-0.74

-3.50%

3,938.40

-31.20

-0.79%

77,508.27

+623.52

+0.81%

Crude Oil Dec 26

95.85

-0.61

-0.63%

US Private Equity

10,836.30

-14.33

-0.13%

NasdaqCM - Nasdaq Real Time Price USD

Akebia Therapeutics, Inc. (AKBA)

0.7118 +0.0034 (+0.48%)

As of 1:56:25 PM EST. Market Open.

Loading Chart for AKBA

Chart Range Bar

Interval:

In partnership with ChartIQ

Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum

Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum

Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026

Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston

Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ...

Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ...

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

Akebia Therapeutics Q2 Earnings Call Highlights

Akebia Therapeutics Q2 Earnings Call Highlights

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036

Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036

Mobilize your Website

View Site in Mobile | Classic

Share by: